MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
August 02 2023 - 8:30AM
Business Wire
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the
“Company”), a clinical stage pharmaceutical company committed to
developing novel therapies for age-related diseases, autoimmune and
inflammatory conditions, announced statistically significant
positive topline Phase 2 results for its next generation Oral TNF-α
inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this
week. In conjunction with its release, the company also announced
it will hold a conference call today, August 2nd, at 4:30pm ET to
discuss the results.
To participate in the conference call, please register here. A
webcast can also be accessed under the ‘Events & Presentations’
section on the Investors page at www.MYMD.com. A replay of the
webcast will be archived on the MyMD website for 30 days.
About MYMD-1
MYMD-1, a next generation, oral selective inhibitor of tumor
necrosis factor-alpha (TNF-α), a driver of chronic inflammation, is
being studied to slow the aging process, prevent sarcopenia and
frailty, and extend healthy lifespan. Its ease of oral dosing is a
significant differentiator compared to currently available TNF-α
inhibitors, all of which require delivery by injection or
infusion.
MYMD-1 has shown effectiveness in pre-clinical and clinical
studies in regulating the immune system. Unlike other therapies,
MYMD-1 has been shown in these studies to selectively block TNF-α
when it becomes overactivated in autoimmune diseases and cytokine
storms, but not block it from doing its normal job of being a first
responder to any routine type of moderate infection. In addition,
it has not been shown to cause serious side effects common with
traditional immunosuppressive therapies that treat
inflammation.
About MyMD Pharmaceuticals
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), is a clinical stage
biopharma company developing groundbreaking therapies for the
treatment of serious and debilitating autoimmune and inflammatory
diseases. MyMD’s lead clinical candidate, MYMD-1®, is an
orally available next-generation TNF-α inhibitor with the potential
to transform the way that TNF-α based diseases are treated.
MYMD-1®, with its small molecule design, improved safety
profile and ability to cross the blood brain barrier, has the
promise to provide meaningful therapeutic solutions to patients not
served by current TNF-α inhibitors and as a potential therapy for
CNS-based inflammatory and autoimmune diseases. The company has
completed Phase 2 studies of MYMD-1® for sarcopenia/frailty,
a result of the aging process, as well as early-stage trials for
rheumatoid arthritis (RA), with the potential to expand into other
applications.
MyMD’s second therapeutic candidate is Supera-CBD, a novel,
synthetic, non-toxic cannabidiol (CBD) analog that is 8000 times
more potent a CB2 agonist (activator) than plant-based CBD. The
U.S. Drug Enforcement Administration (DEA)’s scientific review
concluded Supera-CBD will not be considered a controlled substance
or listed chemical under the Controlled Substances Act (CSA) and
its governing regulations or require scheduling during development.
In addition to its potential role in managing addiction, anxiety,
chronic pain and seizures, Supera-CBD has also been shown to have
anti-inflammatory effects. For more information, visit
www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance, or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the COVID-19 pandemic or
similar public health emergencies on MyMD’s results of operations,
business plan and the global economy. A discussion of these and
other factors with respect to MyMD is set forth in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022,
filed by MyMD on March 31, 2023, as may be supplemented or amended
by the Company’s Quarterly Reports on Form 10-Q. Forward-looking
statements speak only as of the date they are made and MyMD
disclaims any intention or obligation to revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230802047601/en/
Investor: Robert Schatz (646) 421-9523
rschatz@mymd.com
Media: Christy Curran Sam Brown, Inc. (615) 414-8668
christycurran@sambrown.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Apr 2023 to Apr 2024